Ryan Bruce Corcoran

2006 Stanford University, Palo Alto, CA 
"Ryan Corcoran"


Sign in to add mentor
Matthew P. Scott grad student 2006 Stanford
 (The role of sterols and insulin-like growth factor 2 in medulloblastoma tumorigenesis.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Russo M, Siravegna G, Blaszkowsky LS, et al. (2015) Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discovery
Kwak EL, Ahronian LG, Siravegna G, et al. (2015) Molecular heterogeneity and receptor co-amplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discovery
Corcoran RB, Atreya CE, Falchook GS, et al. (2015) Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ahronian LG, Sennott EM, Van Allen EM, et al. (2015) Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery. 5: 358-67
Alagesan B, Contino G, Guimaraes AR, et al. (2015) Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 396-404
Zhu Z, Aref AR, Cohoon TJ, et al. (2014) Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discovery. 4: 452-65
Faber AC, Coffee EM, Costa C, et al. (2014) mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discovery. 4: 42-52
Corcoran RB, Rothenberg SM, Hata AN, et al. (2013) TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Science Translational Medicine. 5: 196ra98
Corcoran RB, Cheng KA, Hata AN, et al. (2013) Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 23: 121-8
Corcoran RB, Ebi H, Turke AB, et al. (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discovery. 2: 227-35
See more...